TYRO3 inhibition led to tumour cell ferroptosis through the AKT‐NRF2 pathway, altering the macrophage ratio and potentially overcoming resistance to anti‐PD‐1 therapy resistance. The gene discussed is PDCD1; the disease is neoplasm.